Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia ... in addition to indication benchmarks based off 18 years of historical drug development data. Attributes ...

A whistleblower accusing Allergan Inc. of engaging in a kickback scheme to increase purchases of “Lap-Band’ obesity devices can advance a portion of his suit toward trial, a Maryland federal judge ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

While CEO Robert Michael said during the conference that the pharma will “commit less capital” to developing psychiatric therapies, according to Reuters, the BMO note indicates that AbbVie still ...

According to the company, Walmart's updated logo is inspired by his trucker hat. (Luke Frazza/AFP/Getty Images) According to Business Insider, Walmart has rolled out seven different logos prior ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie leaders are “disappointed” with poor ...

AbbVie returned to modest growth in 2024 and 2025 figures to be a return to “robust growth," according to the CEO. Through 2029, the company envisions sales will grow in the high-single-digit ...

Wells Fargo & Company increased their price objective on shares of AbbVie to $195.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th.